OrthoPediatrics Corp. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect four (4) directors, each to serve until the 2029 annual meeting of our stockholders: David R. Pelizzon

OrthoPediatrics Corp.’s own tally for this item (“Elect Director: David R. Pelizzon”): 18,056,773 for, 796,241 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(the "Company") held its 2026 Annual Meeting of Stockholders and the Company's stockholders voted on the following matters: Election of Directors The nominees below were elected to serve as directors for a term that will last until the Company's 2029 Annual Meeting of Stockholders or until his or h…”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 4,372,597 for, 194,706 withheld, 2 abstained.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: To elect four (4) directors, each to serve until the 2029 annual meeting of our stockholders: George S. M. Dyer, MD

OrthoPediatrics Corp.’s own tally for this item (“Elect Director: George S. M. Dyer”): 10,843,747 for, 8,009,267 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(the "Company") held its 2026 Annual Meeting of Stockholders and the Company's stockholders voted on the following matters: Election of Directors The nominees below were elected to serve as directors for a term that will last until the Company's 2029 Annual Meeting of Stockholders or until his or h…”
Support: 58% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 522,559 for, 4,044,725 withheld, 21 abstained.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: To elect four (4) directors, each to serve until the 2029 annual meeting of our stockholders: Harald Ruf

OrthoPediatrics Corp.’s own tally for this item (“Elect Director: Harald Ruf”): 18,077,260 for, 775,754 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(the "Company") held its 2026 Annual Meeting of Stockholders and the Company's stockholders voted on the following matters: Election of Directors The nominees below were elected to serve as directors for a term that will last until the Company's 2029 Annual Meeting of Stockholders or until his or h…”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 4,372,603 for, 194,700 withheld, 2 abstained.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: To elect four (4) directors, each to serve until the 2029 annual meeting of our stockholders: Kelly Fischer

OrthoPediatrics Corp.’s own tally for this item (“Elect Director: Kelly Fischer”): 18,535,024 for, 317,990 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(the "Company") held its 2026 Annual Meeting of Stockholders and the Company's stockholders voted on the following matters: Election of Directors The nominees below were elected to serve as directors for a term that will last until the Company's 2029 Annual Meeting of Stockholders or until his or h…”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 4,430,648 for, 136,656 withheld, 1 abstained.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: TO APPROVE AN AMENDMENT TO THE 2024 INCENTIVE AWARD PLAN.

OrthoPediatrics Corp.’s own tally for this item (“Approval, of an amendment to the 2024 Incentive Award Plan ("Plan") to increase the number of shares authorized under the Plan by 2,050,000 shares, which would increase the total number of shares to 3,679,000 The Company”): 18,545,409 for, 272,115 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Approval, of an amendment to the 2024 Incentive Award Plan ("Plan") to increase the number of shares authorized under the Plan by 2,050,000 shares, which would increase the total number of shares to 3,679,000 The Company's stockholders approved the amendment to the 2024 Incentive Award Plan by voti…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 4,402,095 for, 165,210 against.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of our executive officers who are named in the compensation disclosures in this proxy statement.

OrthoPediatrics Corp.’s own tally for this item (“Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved the compensation of the Company's named executive officers by voting as follows:”): 15,953,457 for, 2,859,793 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved the compensation of the Company's named executive officers by voting as follows:”
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 53 managers: 3,183,253 for, 1,412,127 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 125 managers: 6,309,035 for, 2,279,082 against, 34 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.

OrthoPediatrics Corp.’s own tally for this item (“Approval, on an advisory basis, of the appointment of Deloitte & Touche LLP as the Company's Independent Registered Public Accounting Firm for our Fiscal Year Ending December 31, 2026 The Company's stockholders approved ”): 20,479,183 for, 154,131 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Approval, on an advisory basis, of the appointment of Deloitte & Touche LLP as the Company's Independent Registered Public Accounting Firm for our Fiscal Year Ending December 31, 2026 The Company's stockholders approved the appointment by the Audit Committee of the Company's Board of Directors of D…”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 4,553,052 for, 6 against.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.